Brief: Impel Says First Patient Dosed In Phase 2A Study Evaluating INP105
19/07/2022 14:41
July 19 (Reuters) - Impel Pharmaceuticals Inc IMPL.O :
* IMPEL PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 2A
STUDY EVALUATING INP105 TO TREAT ACUTE AGITATION IN ADOLESCENTS
WITH AUTISM SPECTRUM DISORDER (ASD)
Source text for Eikon: ID:nGNX1ljv10
Further company coverage: IMPL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IPI Legacy Liquidation Co
See all newsBrief: Impel Pharmaceuticals- On Dec 19, 2023, Co And Impel NeuroPharma Australia Commenced Voluntary Chapter 11 Proceedings
Brief: Impel Pharmaceuticals Says On Dec 1 Michael Kalb Gave Notice Of Resignation From Position As CFO With Last Day To Be December 31
U.S. STOCKS ON THE MOVE-iRobot Corp, Faraday Future, Fisker
U.S. STOCKS ON THE MOVE-iRobot Corp, Fisker Inc, International Seaways Inc
Brief: Impel Pharmaceuticals Receives Delisting Notice From Nasdaq